Angiogenesis, Exudation, and Degeneration 2027 – Virtual Edition is organized by Bascom Palmer Eye Institute and will be held from Feb 06 - 13, 2027.
Description:
Angiogenesis 2027 continues the tradition of excellence established by Bascom Palmer’s widely acclaimed annual Angiogenesis Meeting/Program, since 2004. The event will be presented as a two-part program on Saturday, February 6, 2027, and Saturday, February 13, 2027. Designed for retina specialists, general ophthalmologists, researchers, and industry professionals, the course will review the latest advances in imaging, translational research, and clinical trials, with emphasis on their impact on clinical ophthalmology.
The February 6 session will focus only on age-related macular degeneration (AMD), highlighting investigator-initiated research, emerging therapies, and both ongoing and recently completed clinical trials related to diagnosis and treatment along with the addition of panel discussions featuring international experts.
The February 13 session will focus on retinal vascular diseases, including diabetic retinopathy and retinal vascular occlusions, with emphasis on emerging therapies, clinical trial results, and advances in patient management.
Course Objectives:
Upon completion of this course, participants should be able to:
- Analyze emerging structural, functional, and perfusion biomarkers associated with the development and progression of age-related macular degeneration (AMD).
- Interpret advances in multimodal retinal imaging and artificial intelligence–based approaches for assessing disease activity, progression risk, and treatment response in retinal disease.
- Evaluate evolving concepts in the pathobiology of nonexudative AMD and geographic atrophy, including mechanisms associated with retinal degeneration and perfusion abnormalities.
- Assess the strengths, limitations, and clinical relevance of novel clinical trial endpoints, outcome measures, and study designs used in retinal disease research.
- Review current evidence supporting approved therapies for geographic atrophy and incorporate real-world outcome data into treatment decision-making.
- Compare emerging pharmacologic, gene-based, cell-based, and regenerative therapies in development for nonexudative AMD.
- Evaluate investigational therapies and pivotal clinical trial results that may influence future management of neovascular AMD.
- Discuss advances in long-acting delivery systems, gene therapies, and next-generation anti-VEGF strategies designed to improve durability and visual outcomes in exudative retinal disease.
- Interpret multimodal retinal imaging, functional testing, and emerging artificial intelligence–based biomarkers to diagnose and assess retinal vascular disease
- Evaluate clinical trial and real-world evidence regarding the efficacy, safety, durability, and treatment burden of approved and investigational therapies for retinal vascular disease.
- Integrate biomarkers and patient-specific findings to develop evidence-based, individualized treatment strategies for retinal vascular disease.